CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
RIBBON-LA-01
Phase 2 other active
Quick answer
CCRT with Maintenance Tislelizumab and Metronomic Capecitabine for Nasopharyngeal Carcinoma is a Phase 2 program (other) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Modality
- other
- Status
- active